论文部分内容阅读
The new oxovanadium (V) complex, [PyH][VO2(L)] 1 (salicyladehyde 5-bromo salicyloylhydrazone is abbreviated as H2L; Hpy is protonated pyridine) was obtained from a refluxed solution of VOSO4 and H2L in acetonitrile-methanol-pyridine. Similarly, another new complex, [VO(L)(OCH3)] 2 was synthesized by refluxing VOSO4 and H2L in methanol-pyridine. Crystal data for 1: C19H15N3O5BrV, Mr= 496.2, monoclinic, P21/n, a = 7.1885(3), b = 9.2718(3), c = 28.803(1) A, β = 96.185(1)°, Z = 4 and V = 1908.6(1) A3; for 2: C15H12N2O5BrV, Mr= 431.1, monoclinic, P2,/n, a = 12.202(2), b = 8.045(2), c = 16.604(3) A, β = 101.29(3)°, Z = 4 and V = 1598.4(2) A3. The structures of 1 and 2 have been determined by X-ray analyses and reveal that the coordination environments of V atoms in both complexes are of square-based pyramid. Three of the four based donor atoms are from the tridentate “ONO” donor ligand while the fourth is one terminal oxygen atom with the V(1) - O(3) distance 1.646(4) A for 1 and one -OCH3 group with the V
The new oxovanadium (V) complex, [PyH] [VO2 (L)] 1 (salicyladehyde 5-bromo salicyloylhydrazone is abbreviated as H2L; Hpy is protonated pyridine) was obtained from a refluxed solution of VOSO4 and H2L in acetonitrile-methanol-pyridine , Another new complex, [VO (L) (OCH3)] 2 was synthesized by refluxing VOSO4 and H2L in methanol-pyridine. Crystal data for 1: C19H15N3O5BrV, Mr = 496.2, monoclinic, P21 / n, a = 7.1885 B = 9.2718 (3) c = 28.803 (1) A, β = 96.185 (1) °, Z = 4 and V = 1908.6 A3; for 2: C15H12N2O5BrV, Mr = 431.1, monoclinic, P2 , / n, a = 12.202 (2), b = 8.045 (2), c = 16.604 (3) A, β = 101.29 (3) °, Z = 4 and V = 1598.4 and 2 have been determined by X-ray analyzes and reveal that the coordination environments of V atoms in both complexes are of square-based pyramid. Three of the four based donor atoms are from the tridentate “ONO” donor ligand while the fourth is one terminal oxygen atom with the V (1) - O (3) distance 1.646 (4) A for 1 and one - OCH3 group with the V